Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion

References

• Göke R, Fehmann HC, Göke B. Glucagon-like peptide-1(7–36) amide is a new incretin/enterogastrone candidate. Eur J Clin Invest 1991;21:135–44.
   PubMed Web of Science ®Google Scholar
• Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992;22:283–91.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 1997;273:E981–8.
   PubMed Web of Science ®Google Scholar
• Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006;91:1916–23.
   PubMed Web of Science ®Google Scholar
• Kielgast, Holst JJ, Madsbad S. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev 2009;5:266–75.
   PubMedGoogle Scholar
• Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665–73.
   PubMed Web of Science ®Google Scholar
• Schirra J, Katschinski M, Weidmann C, Schäfer T, Wank U, Arnold R, Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996:97:92–103.
   PubMed Web of Science ®Google Scholar
• Willms B, Werner J, Ørskov C, Holst JJ, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7—36) amide in type 2 (noninsulin dependent) diabetic patients. J Clin Endocrinol Metab 1996;81:327–32.
   PubMed Web of Science ®Google Scholar
• Schirra J, Kuwert P, Wank U, Leicht P, Arnold R, Göke B, Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc Assoc Am Physicians 1997;109:84–97.
   PubMedGoogle Scholar
• Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol 2002;282:G424–31.
   PubMed Web of Science ®Google Scholar
• Näslund E, Bogefors J, Skogar S, Grybäck P, Jacobsson H, Holst JJ, GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999;277:R910–6.
   PubMed Web of Science ®Google Scholar
• Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide-1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2719–25.
   PubMed Web of Science ®Google Scholar
• Wettergren A, Maina P, Boesby S, Holst JJ. Glucagon-like peptide-1 7-36 amide and PYY have additive inhibitory effect on gastric acid secretion in man. Scand J Gastroenterol 1997;32:552–5.
   PubMed Web of Science ®Google Scholar
• Camilleri M. Integrated upper gastrointestinal response to food intake. Gastroenterology 2006;131:640–58.
   PubMed Web of Science ®Google Scholar
• Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007;56:1475–80.
   PubMed Web of Science ®Google Scholar
• Woerle H, Lindenberger T, Linke R, Foley J, Ligueros-Saylan M, Zhang Y, A single dose of vildagliptin (VILDA) decelerates gastric emptying (GE) in patients with type 2 diabetes (T2DM). Diabetes 2007;56:A133 (Abstract).
   Google Scholar
• Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 2009;23:479–86.
   PubMed Web of Science ®Google Scholar
• Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M. Ex(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 1998;101:1421–30.
   PubMed Web of Science ®Google Scholar
• Salehi M, Vahl TP, D'Allessio DA. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. J Clin Endocrinol Metab 2008;93:4909–16.
   PubMed Web of Science ®Google Scholar
• Deane AM, Nguyen NQ, Stevens JE, Fraser RJ, Holloway RH, Besanko LK, Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010;95:215–21.
   PubMed Web of Science ®Google Scholar
• Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M, Göke B. GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterol Motil 2009;21:609–18.
   PubMedGoogle Scholar
• Verdich C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86:4382–9.
   PubMed Web of Science ®Google Scholar
• Grybäck P, Hermansson G, Lyrenäs E, Beckman KW, Jacobsson H, Hellström PM. Nationwide standardisation and evaluation of scintigraphic gastric emptying: reference values and comparisons between subgroups in a multicentre trial. Eur J Nucl Med 2000;27:647–55.
   PubMedGoogle Scholar
• Holst JJ. Evidence that enteroglucan (II) is identical with the C-terminal sequence (residues 33–39) of glicentin. Biochem J 1982;207:381–8.
   PubMed Web of Science ®Google Scholar
• Schmidt PT, Ljung T, Hartmann B, Hare KJ, Holst JJ, Hellström PM. Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY. Eur J Gastroenterol Hepatol 2005;17:207–12.
   PubMedGoogle Scholar
• Schirra J, Houk P, Wank U, Arnold R, Göke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 2000;46:622–31.
   PubMed Web of Science ®Google Scholar
• Schirra J, Wank U, Arnold R, Göke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut 2002;50:341–8.
   PubMedGoogle Scholar
• Villsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Incretin secretion in relation to meal size and body weight in healthy subjects and people with Type 1 and Type 2 diabetes mellitus. J Clin Endocrinol Metab 2003;88:2706–13.
   PubMedGoogle Scholar
• Hansen L, Hartmann B, Bisgaard T, Mineo H, Jørgensen PN, Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol 2000;278:E1010–8.
   PubMed Web of Science ®Google Scholar
• Gutniak MK, Ørskov C, Holst JJ, Ahrén B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-37) in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326:1316–22.
   PubMed Web of Science ®Google Scholar
• Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans. Diabetes 1999;48:86–93.
   PubMed Web of Science ®Google Scholar
• Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006;55:243–51.
   PubMed Web of Science ®Google Scholar
• Salehi M, Aulinger B, Prigeon RL, D'Alessio DA. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes 2010;59:1330–7.
   PubMed Web of Science ®Google Scholar
• Jonderko G, Gołab T, Jonderko K. A pharmacological dose of glucagon suppresses gastric emptying of a radiolabelled solid meal in humans. Scand J Clin Lab Invest 1988;48:743–6.
   PubMed Web of Science ®Google Scholar
• Kong MF, King P, MacDonald IA, Blackshaw PE, Perkins AC, Armstrong E, Effect of euglycaemic hyperinsulinaemia on gastric emptying and gastrointestinal hormone responses in normal subjects. Diabetologia 1998;41:474–81.
   PubMed Web of Science ®Google Scholar